Skip to content
MarketScale
‹ Back to IndustriesSciences

5 Space Bound Companies That Can Get Your Business to the Moon

In 1969 Neil Armstrong took his famous first steps on the moon. In the half century since, only a select few have followed in his path. However, the private sector is intent on changing that soon. Here are five companies that are working towards making commercial space travel possible in the near future. 1. SpaceX…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Geoff Short · Blue OriginBoeingCommercial Space FlightElon Musk
Share
5 Space Bound Companies That Can Get Your Business to the Moon

Key takeaways

01

In 1969 Neil Armstrong took his famous first steps on the moon.

02

In the half century since, only a select few have followed in his path.

03

However, the private sector is intent on changing that soon.

In 1969 Neil Armstrong took his famous first steps on the moon. In the half century since, only a select few have followed in his path. However, the private sector is intent on changing that soon.

Here are five companies that are working towards making commercial space travel possible in the near future.

1. SpaceX

Elon Musk started SpaceX in 2002 and has since achieved several historic milestones. In 2010 it became the first private company to successfully return a spacecraft from low Earth orbit. It also delivered cargo to the International Space Station in 2012. SpaceX has now conducted more than 100 test launches.

2. Blue Origin

Blue Origin dates back to 2000, and like SpaceX, was also founded by a billionaire. Jeff Bezos has the ambition to make life on Mars a reality but is also focused on commercial flights to space with the idea of safely returning passengers.

3. Virgin Galactic

Another commercial space flight program, another billionaire founder. Richard Branson’s Virgin Galactic hopes to send passengers to space every 32 hours within the next four years, according to a document released by the Securities and Exchange Commission this week. Business Insider reports that tickets to space on Virigin Galactic would cost $250,000.

4. Rocket Lab

Smallset launch service provider Rocket Lab is on a mission to open space to explorers everywhere. By providing a sustainable satellite launch system cheaper and faster, companies will be able to build a roadmap among the stars. The company, which has offices in California and New Zealand, is hoping to meet the increasing demand of commercial space launches.

5. Boeing

Also facilitating other companies’ space launches is Boeing. The company has manufactured parts for commercial, research and military space missions. These include satellites, GPS devices, launch systems and more. Particularly, Boeing is working with NASA to create a gateway for trips to the lunar surface and eventually Mars.

About the author

GS
Geoff Short

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

GS
Geoff Short